Double blow for Sangamo as Novartis, Biogen exit deals

Gene-editing specialist Sangamo Therapeutics has lost not one but two sizeable partnerships with larger biopharma companies, with Novartis and Biogen both walking away fro

4DMT's Fabry gene therapy on hold, but 'remains active'

4D Molecular Therapeutics (4DMT) has said a trial of its gene therapy for Fabry disease has been placed on a clinical hold by the FDA, a few weeks after it reported three

Pfizer, Sangamo resume haemophilia gene therapy trial

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene fitelparvovec, after the FDA lifted a clinical hold on t

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

Gene therapy biotech shares sink on inconclusive trial resul...

Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results in early clinical trials.

Sangamo edits living patient's DNA for first time

Doctors in California have made history by attempting to edit genes within a patient for the first time, when 44 year-old Brian Madeux received the experimental therapy to correct a DNA def